A review of safety and immunogenicity of a novel measles, mumps, rubella (MMR) vaccine

References

• Kauffmann F, Heffernan C, Meurice F, Ota MOC, Vetter V, Casabona G. Measles, mumps, rubella prevention: how can we do better? Expert Rev Vaccines. 2021;20(7):811–8. doi:10.1080/14760584.2021.1927722.
   PubMed Web of Science ®Google Scholar
• Portnoy A, Jit M, Ferrari M, Hanson M, Brenzel L, Verguet S. Estimates of case-fatality ratios of measles in low-income and middle-income countries: a systematic review and modelling analysis. Lancet Glob Health. 2019;7(4):472–81. doi:10.1016/S2214-109X(18)30537-0.
   Web of Science ®Google Scholar
• Vaidyanathan G. Massive measles outbreak threatens India’s goal to eliminate disease by 2023. 2022 Dec. https://www.nature.com/articles/d41586-022-04480-z.
   Google Scholar
• Moving towards the measles and rubella elimination goal in India. 2022 Mar 14. https://www.who.int/india/news/feature-stories/detail/moving-towards-the-measles-and-rubella-elimination-goal-in-india.
   Google Scholar
• Govt: 40 kids killed, 10,000 affected by measles this year; Maharashtra worst hit. 2022 Dec 20. https://timesofindia.indiatimes.com/india/govt-40-kids-killed-10000-affected-by-measles-this-year-maharashtra-worst-hit/articleshow/96355047.cms.
   Google Scholar
• Karade S, Sen S, Sashindran V, Sharma P, Kanitkar M. Measles, mumps, and rubella: a cross-sectional study of susceptibility to vaccine-preventable diseases among young people in India. Med J Armed Forces India. 2019;75(1):70–3. doi:10.1016/j.mjafi.2018.12.010.
   PubMedGoogle Scholar
• Mumps-for healthcare providers. 2021. https://www.cdc.gov/mumps/hcp.html
   Google Scholar
• Shanmugasundaram D, Awasthi S, Dwibedi B, Geetha S, Jain M, Malik S, Patel B, Singh H, Tripathi S, Viswanathan R. et al. Burden of congenital rubella syndrome (CRS) in India based on data from cross-sectional serosurveys, 2017 and 2019–20. PLoS Negl Trop Dis. 2021;15(7):e0009608. doi:10.1371/journal.pntd.0009608.
   PubMed Web of Science ®Google Scholar
• Winter AK, Pramanik S, Lessler J, FERRARI M, GRENFELL BT, METCALF CJE. Rubella vaccination in India: identifying broad consequences of vaccine introduction and key knowledge gaps. Epidemiol Infect. 2018;146(1):65–77. doi:10.1017/S0950268817002527.
   PubMed Web of Science ®Google Scholar
• Vynnycky E, Adams EJ, Cutts FT, Reef SE, Navar AM, Simons E, Yoshida L-M, Brown DWJ, Jackson C, Strebel PM. et al. Using seroprevalence and immunisation coverage data to estimate the global burden of congenital rubella syndrome, 1996-2010: a systematic review. PLoS One. 2016;11(3):e0149160. doi:10.1371/journal.pone.0149160.
   PubMed Web of Science ®Google Scholar
• Sood A, Mitra M, Joshi HA, Nayak US, Siddaiah P, Babu TR, Mahapatro S, Sanmukhani J, Gupta G, Mittal R. et al. Immunogenicity and safety of a novel MMR vaccine (live, freeze-dried) containing the Edmonston-Zagreb measles strain, the Hoshino mumps strain, and the RA 27/3 rubella strain: results of a randomized, comparative, active controlled phase III clinical trial. Hum Vaccin Immunother. 2017;13(7):1523–1530. doi:10.1080/21645515.2017.1302629.
   PubMed Web of Science ®Google Scholar
• Murhekar MV, Gupta N, Hasan AZ, Kumar MS, Kumar VS, Prosperi C, Sapkal GN, Thangaraj JWV, Kaduskar O, Bhatt V. et al. Evaluating the effect of measles and rubella mass vaccination campaigns on seroprevalence in India: a before-and-after cross-sectional household serosurvey in four districts, 2018–2020. Lancet Glob Health. 2022;10(11):1655–64. doi:10.1016/S2214-109X(22)00379-5.
   Google Scholar
• Madhanraj K, Singh N, Gupta M, Singh MP, Ratho RK. An outbreak of rubella in Chandigarh, India. Indian Pediatr. 2014;51:897–9. doi:10.1007/s13312-014-0523-8.
   PubMed Web of Science ®Google Scholar
• National family health survey (NFHS-4) 2015-16. https://dhsprogram.com/pubs/pdf/fr339/fr339.pdf.
   Google Scholar
• Introduction of measles rubella vaccine (campaign and routine immunization) national operational guidelines. In: Ministry of Health and family welfare GoI, editor; 2017.
   Google Scholar
• FOGSI good clinical practice recommendations on preconception care-india. p. 12.
   Google Scholar
• Di Pietrantonj C, Rivetti A, Marchione P, Debalini MG, Demicheli V. Vaccines for measles, mumps, rubella, and varicella in children. Cochrane Database Syst Rev. 2020;(4). doi:10.1002/14651858.CD004407.pub4.
   PubMed Web of Science ®Google Scholar
• Kasi SG, Shivananda S, Marathe S, Chatterjee K, Agarwalla S, Dhir SK, Verma S, Shah AK, Srirampur S, Kalyani S. et al. Indian Academy of Pediatrics (IAP) Advisory Committee on Vaccines and Immunization Practices (ACVIP): recommended immunization schedule (2020–21) and update on immunization for children aged 0 through 18 years. Indian Pediatr. 2021;58(1):44–53. doi:10.1007/s13312-021-2096-7.
   PubMed Web of Science ®Google Scholar
• Vashishtha VM, Choudhury P, Kalra A, Bose A, Thacker N, Yewale VN, Bansal CP, Mehta PJ. Indian Academy of Pediatrics (IAP) recommended immunization schedule for children aged 0 through 18 years—India, 2014 and updates on immunization. Indian Pediatr. 2014;51:785–800. doi:10.1007/s13312-014-0504-y.
   PubMed Web of Science ®Google Scholar
• Requirements for measles, mumps and rubella vaccines and combined vaccine (live), Annex 3, TRS No 840 [Internet]. 3 July 1994.
   Google Scholar
• Arruda WO, Kondageski C. Aseptic meningitis in a large MMR vaccine campaign (590,609 people) in Curitiba, Parana, Brazil, 1998. Revista do Instituto de Medicina Tropical de São Paulo. 2001;43:301–2. doi:10.1590/S0036-46652001000500012.
   PubMedGoogle Scholar
• Tešović G, Begovac J, Baće A. Aseptic meningitis after measles, mumps, and rubella vaccine. Lancet. 1993;341(8859):1541. doi:10.1016/0140-6736(93)90684-9.
   PubMed Web of Science ®Google Scholar
• da Silveira CM, Kmetzsch CI, Mohrdieck R, Sperb,AF, Prevots DR. The risk of aseptic meningitis associated with the Leningrad-Zagreb mumps vaccine strain following mass vaccination with measles-mumps-rubella vaccine, Rio Grande do Sul, Brazil, 1997. Int J Epidemiol. 2002;31(5):978–82.
   PubMed Web of Science ®Google Scholar
• Ozaki T, Goto Y, Nishimura N, Nakano T, Kumihashi H, Kano M, Ohfuji S. Effects of a public subsidy program for mumps vaccine on reducing the disease burden in Nagoya city, Japan. Jpn J Infect Dis. 2019;72(2):106–11. doi:10.7883/yoken.JJID.2018.276.
   PubMed Web of Science ®Google Scholar
• Esteghamati A, Keshtkar A, Heshmat R. Gouya MM, Salar AM, Armin S, Mahoney F. Adverse reactions following immunization with MMR vaccine in children at selected provinces of Iran. 2011.
   Google Scholar
• Ki M, Park T, Yi SG, Oh JK, Choi B. Risk analysis of aseptic meningitis after measles-mumps-rubella vaccination in Korean children by using a case-crossover design. Am J Epidemiol. 2003;157(2):158–65. doi:10.1093/aje/kwf167.
   PubMed Web of Science ®Google Scholar
• Kitano T. Close the gap for routine mumps vaccination in Japan. Hum Vaccin Immunother. 2021;17(1):205–210. doi:10.1080/21645515.2020.1765619.
   PubMed Web of Science ®Google Scholar
• Shah N, Parikh R, Casabona G, Kolhapure S. A new combined vaccine against measles, mumps, rubella and varicella in India. Indian Pediatr. 2017;54:1041–6. doi:10.1007/s13312-017-1209-9.
   PubMed Web of Science ®Google Scholar
• Lee C-Y, Tang R-B, Huang F-Y, Tang H, Huang L-M, Bock HL. A new measles mumps rubella (MMR) vaccine: a randomized comparative trial for assessing the reactogenicity and immunogenicity of three consecutive production lots and comparison with a widely used MMR vaccine in measles primed children. Int J Infect Dis. 2002;6(3):202–9. doi:10.1016/S1201-9712(02)90112-8.
   PubMedGoogle Scholar
• Measles, mumps, and rubella (mmr) vaccine price of 5 brands. 2023. https://www.medindia.net/drug-price/measles-mumps-and-rubella-mmr-vaccine.htm
   Google Scholar
• Malaiyan J, Menon T. Low vaccine efficacy of mumps component among MMR vaccine recipients in Chennai, India. Indian J Med Res. 2014;139:773–5.
   PubMed Web of Science ®Google Scholar
• da Cunha SS, Rodrigues LC, Barreto M, Dourado I. Outbreak of aseptic meningitis and mumps after mass vaccination with MMR vaccine using the Leningrad–Zagreb mumps strain. Vaccine. 2002;20(7–8):1106–12. doi:10.1016/S0264-410X(01)00438-8.
   PubMed Web of Science ®Google Scholar
• Bhowmik E, Singh A, Sachan R. Profile of adverse events following immunization with measles rubella vaccine at a tertiary care hospital in East Delhi, India. Ther Adv Vaccines Immunother. 2020;8:2515135520940131. doi:10.1177/2515135520940131.
   Google Scholar
• Bhatnagar N, Kaur R, Gupta M, Sharma D. Introducing combined measles, mumps and rubella vaccine in Chandigarh, India: issues and concerns! Indian Pediatr. 2014;51:441–3. doi:10.1007/s13312-014-0428-6.
   PubMed Web of Science ®Google Scholar
• Gupta M, Tripathy JP, Verma M, Singh, M., Kaur, R., Ratho, R.K, Kumar, R. Seroprevalence of measles, mumps & rubella antibodies among 5-10 years old children in North India. Indian J Med Res. 2019;149(3):396. doi:10.4103/ijmr.IJMR_1453_17.
   PubMed Web of Science ®Google Scholar
• Wellington K, Goa KL. Measles, mumps, rubella vaccine (Priorix™ GSK-MMR) a review of its use in the prevention of measles, mumps and rubella. Drugs. 2003;63:2107–26. doi:10.2165/00003495-200363190-00012.
   PubMed Web of Science ®Google Scholar
• Miller E, Farrington P, Goldracre M, Pugh S, Colville A, Flower A, Nash J, Macfarlane L, Tettmar R. Risk of aseptic meningitis after measles, mumps, and rubella vaccine in UK children. Lancet. 1993;341(8851):979–82. doi:10.1016/0140-6736(93)91069-X.
   PubMed Web of Science ®Google Scholar
• Sharma H, Oun SA, Abou Bakr S, Kapre SV, Jadhav SS, Dhere RM, Bhardwaj S. No demonstrable association between the Leningrad–Zagreb mumps vaccine strain and aseptic meningitis in a large clinical trial in Egypt. Clin Microbiol Infect. 2010;16(4):347–52. doi:10.1111/j.1469-0691.2010.03121.x.
   PubMed Web of Science ®Google Scholar
• Atrasheuskaya A, Kulak M, Fisenko EG, Karpov I, Ignatyev G, Atrasheuskaya A. Horizontal transmission of the Leningrad–Zagreb mumps vaccine strain: a report of six symptomatic cases of parotitis and one case of meningitis. Vaccine. 2012;30(36):5324–6. doi:10.1016/j.vaccine.2012.06.055.
   PubMed Web of Science ®Google Scholar
• Tešović G, Poljak M, Lunar MM, Kocjan BJ, Seme K, Vukić BT, Sternak SL, Čajić V, Vince A. Horizontal transmission of the Leningrad–Zagreb mumps vaccine strain: a report of three cases. Vaccine. 2008;26(16):1922–5. doi:10.1016/j.vaccine.2008.02.014.
   PubMed Web of Science ®Google Scholar
• Vukić BT, Pavić I, Milotić I, Slavuljica I. Aseptic meningitis after transmission of the Leningrad–Zagreb mumps vaccine from vaccinee to susceptible contact. Vaccine. 2008;26(38):4879. doi:10.1016/j.vaccine.2008.06.096.
   PubMed Web of Science ®Google Scholar
• Santos B, Ranieri TS, Bercini M, Schermann MT, Famer S, Mohrdieck R, Maraskin T, Wagner MB. An evaluation of the adverse reaction potential of three measles-mumps-rubella combination vaccines. Revista Panamericana de Salud Pública. 2002;12(4):240–6. doi:10.1590/S1020-49892002001000004.
   PubMedGoogle Scholar
• Makino S, Sasaki K, Nakayama T, Oka S, Urano T, Kimura M, Kawana R, Yamamura AM. A new combined trivalent live measles (AIK-C strain), mumps (Hoshino strain), and rubella (Takahashi strain) vaccine findings in clinical and laboratory studies. Am J Dis Child. 1990 Aug;144(8):905–10. doi:10.1001/archpedi.1990.02150320069030.
   PubMedGoogle Scholar
• Nakayama T, Urano T, Osano M, Nakagawa M, Maehara N, Sasaki K, Yamamura AM, Makino S. Evaluation of live trivalent vaccine of measles AIK-C strain, mumps Hoshino strain and rubella Takahashi strain, by virus-specific interferon-γ production and antibody response. Microbiol Immunol. 1990;34(6):497–508. doi:10.1111/j.1348-0421.1990.tb03167.x.
   PubMed Web of Science ®Google Scholar
• Avijgan M, Hafizi M, Moghni M, Kheiri S, Esteghamati A, Sarikhani S. Immunogenicity and efficacy of the Hoshino strain of mumps (MMR vaccine) in Iran. East Afr J Public Health. 2011;8:88–91.
   PubMedGoogle Scholar
• Makino S, Sasaki K, Nakayama T, Oka S, Urano T, Kimura M, Kawana R, Yamamura AM. A new combined trivalent live measles (AIK-C strain), mumps (Hoshino strain), and rubella (Takahashi strain) vaccine: findings in clinical and laboratory studies. Am J Dis Child. 1990;144(8):905–10. doi:10.1001/archpedi.1990.02150320069030.
   PubMedGoogle Scholar
• Gidengil C, Goetz MB, Newberry S, Maglione M, Hall O, Larkin J, Motala A, Hempel S. Safety of vaccines used for routine immunization in the United States: an updated systematic review and meta-analysis. Vaccine. 2021;39(28):3696–716. doi:10.1016/j.vaccine.2021.03.079.
   PubMed Web of Science ®Google Scholar
• Nakayama T, Eda M, Hirano M, Goto, W. Immunogenicity and safety of the new MMR vaccine containing measles AIK-C, rubella Takahashi, and mumps RIT4385 strains in Japanese children: a randomized phase I/II clinical trial. Hum Vaccines Immunother. 2019;15(5):1139–1144. doi:10.1080/21645515.2019.1578591.
   PubMed Web of Science ®Google Scholar
• Organization WH. Mumps virus vaccines. Weekly Epidemiological Record = Relevé épidémiologique hebdomadaire. 2007;82:51–60.
   PubMedGoogle Scholar
• Khanum S, Garelick H, Uddin N, Mann G, Tomkins A. Comparison of Edmonston-Zagreb and Schwarz strains of measles vaccine given by aerosol or subcutaneous injection. Lancet. 1987;329(8525):150–3. doi:10.1016/S0140-6736(87)91978-7.
   Google Scholar
• Izadi S, Zahraei SM, Salehi M, Mohammadi M, Tabatabaei SM, Mokhtari-Azad T. Head-to-head immunogenicity comparison of Edmonston-Zagreb vs. AIK-C measles vaccine strains in infants aged 8–12 months: a randomized clinical trial. Vaccine. 2018;36(5):631–6. doi:10.1016/j.vaccine.2017.12.048.
   PubMed Web of Science ®Google Scholar
• Weibel RE, Villarejos VM, Klein EB, Buynak EB, McLean AA, Hilleman MR. Clinical and laboratory studies of live attenuated RA 27/3 and HPV 77-DE rubella virus vaccines. Proc Soc Exp Biol Med. 1980;165(1):44–9. doi:10.3181/00379727-165-40931.
   PubMed Web of Science ®Google Scholar